Tag: editas medicine
March 20, 2020
The Rise of CRISPR Technology
CRISPR technology is a rapidly growing component of the genetics industry. Here's what investors need to know about its future... January 21, 2019
Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101
Editas Medicine (Nasdaq:EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology...
November 13, 2018
CRISPR Trials to Watch in 2018
CRISPR Cas-9 gene editing is finally in clinical studies. Here's an overview of CRISPR genetics testing trials currently in progress.
June 28, 2018
5 Top NASDAQ Genetic Stocks of Q2 2018
In the final days of Q2 2018, we've profiled the five top NASDAQ genetic stocks year-to-date. Here's a look at...
April 29, 2018
5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent
Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 1, 2018
5 Top NASDAQ Biotech Stocks: Cardiome on Top
Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices. March 27, 2018